June 11 (Reuters) - Merck ( MRK ) is focused on second-

and third-generation opportunities in the cardiometabolic drugs

market, which includes weight-loss treatments, the U.S.

drugmaker said on Tuesday.

"We think more in terms of small molecule orals, versus

injectables. That's the preferred route," CEO Robert Davis said

at the Goldman Sachs global healthcare conference.

Merck ( MRK ) is looking at the additional potential benefits of

weight-loss treatments through drug combinations with "good

tolerability and good combinability".

(Reporting by Mariam Sunny and Sneha S.K. in Bengaluru; Editing

by Krishna Chandra Eluri and Sriraj Kalluvila)